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ABSTRACT
Background and Purpose: To compare the structural and hemodynamic changes of healthy
brain tissue in the cerebral hemisphere contralateral to the tumor following photon and proton
radiochemotherapy.
Materials and Methods: Sixty-seven patients (54.9±14.0 years) diagnosed with glioblastoma
undergoing adjuvant photon (n= 47) or proton (n=19) radiochemotherapy with temozolomide after
tumor resection underwent T1-weighted and arterial spin labeling MRI. Changes in volume and
perfusion before and 3 to 6 months after were compared between therapies.
Results: A decrease in gray matter (GM) (-2.2%, P <0.001) and white matter (WM) (-1.2%,
P <0.001) volume was observed in photon-therapy patients compared to the pre-radiotherapy base-
line. In contrast, for the proton-therapy group, no significant differences in GM (0.3%, P=0.64)
or WM (-0.4%, P=0.58) volume were observed. GM volume decreased with 0.9% per 10 Gy dose
increase (P <0.001) and differed between the radiation modalities (P <0.001). Perfusion decreased
in photon-therapy patients (-10.1%, P=0.002), whereas the decrease in proton-therapy patients,
while comparable in magnitude, did not reach statistical significance (-9.1%, P=0.12). There was
no correlation between perfusion decrease and either dose (P=0.64) or radiation modality (P=0.94).
Conclusions: Our results show that the tissue volume decrease depends on radiation dose delivered
to the healthy hemisphere and differs between treatment modalities. In contrast, the decrease in
perfusion was comparable for both irradiation modalities. We conclude that proton therapy may
reduce brain-volume loss when compared to photon therapy.
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INTRODUCTION
Glioblastoma is the most common primary malignant brain tumor in adults. The standard
therapy is maximal surgical resection followed by radiotherapy (RT) with concurrent and adjuvant
chemotherapy using temozolomide [1]. Both RT and chemotherapy are, however, associated with
risks of cognitive deficits and structural and hemodynamic changes in the normal brain tissue [2, 3].
Brain atrophy may appear as a side-effect of RT and progressive decrease in gray matter (GM)
volume over time and a dependence on radiation dose have been reported after photon RT [4, 5, 6,
7, 8]. Interestingly, no significant changes in white matter (WM) volume were observed in the same
studies, despite findings WM fiber damage following RT from diffusion MRI data [9, 10].
RT was also shown to cause vessel-wall thickening and endothelial cell loss leading to cerebral
microbleeds and occlusions in the microvasculature [11, 12]. These changes could in turn affect the
healthy-tissue perfusion. Several studies have investigated the influence of RT on brain perfusion with
mostly contradictory conclusions. Perfusion decreases have been detected by dynamic susceptibility
contrast and arterial spin labeling (ASL) MRI, and with 99mTc-HMPAO scintigraphy [13, 14, 15, 16];
whereas perfusion increases have been measured using a computed tomography (CT)-perfusion,
dynamic susceptibility contrast MRI, and 15O-H2O PET [17, 18, 19].
We posit that reduction of healthy tissue damage following radiochemotherapy (RCT) may be
achieved by using proton instead of photon RT. Proton therapy offers better dose distribution whilst
exploiting comparable biological effectiveness [20]. In this study, we aimed to assess potential benefits
of proton over photon therapy in terms of reducing damage to healthy brain tissue. We investigated
the early-delayed brain volume and perfusion changes in healthy tissue at 3 and 6 months after
RT, correlated the changes to the delivered radiation dose, and compared the differences between
radiation modalities.
METHODS
Participants and experimental design
The present investigation concerns the first two follow-up sessions of patients treated in the
prospective, two-arm (photon and proton therapy), single-center non-randomized imaging trial “Ob-
servational study of impact of [11C]-methionine PET/MRI as a tool for individual tailoring post-
operative radiochemotherapy for patients with glioblastoma multiforme” (PETra). This trial was
designed to validate the value of [11C]-methionine PET as an imaging biomarker for predicting the
location of recurrence as a basis for future radiotherapy dose-escalation approaches. Patient accrual
lasted from September 2013 until October 2016 and the results according to the endpoints laid down
in the protocol will be reported separately.
The registered trial (NCT01873469) was conducted in accordance with the Declaration of Helsinki
and was approved by the Ethics Committee of the Faculty of Medicine at the Technische Universität
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Dresden, Germany (EK41022013). All patients provided written informed consent.
The main inclusion criteria of the PETra trial included newly diagnosed glioblastoma, age ≥ 18
years and Karnofsky Performance Score ≥ 60. After clinical introduction of proton-beam therapy
at the University Proton Therapy Dresden at December 2014, the choice of treatment with photon
or proton-beam therapy depended on the decision of the treating physician, the patient and on
reimbursement of the costs. The current investigation included only those patients for which MRI
scans prior to initiation of RCT were available, who had unilateral tumor localization before RCT,
who received all planned fractions of photon- or proton-beam irradiation, and who were scanned at
least once after the end of RCT. In total, 72 patients (51 photon, 21 proton) were included in this
imaging study (mean age 54.3±14.2 years, range 23.2 – 81.8 years, 29 female).
The first MR session was performed after surgery and before start of RCT. For each patient,
imaging data also included [11C]-Methionine PET and treatment-planning CT scans. RT treatment
started 2 – 7 weeks after full or partial tumor resection or biopsy. After the end of RT, follow-up
MRI scans were acquired every 3 months for two years or until disease progression or drop out of
the patient. Here we present follow-up data at 3 and 6 months after the end of RT.
Radiation treatment planning was based on the CT and PET/MRI scans. The margin of the
clinical target volume (CTV) around the surgical cavity and macroscopic tumor was 20 mm for the
volume treated up to 50 Gy (2 Gy per fraction) and 5 mm for the boost volume treated with an
additional 10 Gy (2 Gy per fraction) to a total dose of 60 Gy (60 GyE for proton therapy). A 5mm
margin was added for the planning target volume.
Photon-based radiation treatment plans were generated using either 3D conformal radiotherapy
(3DCRT) (Oncentra Masterplan 3.1, Nucletron, Veenendaal, The Netherlands; n=27) or intensity-
modulated radiotherapy (IMRT) (Pinnacle 9.0, Philips, Eindhoven, The Netherlands; n=24). Pho-
ton RT was delivered with linear accelerators with multileaf collimator (Siemens Healthcare, Er-
langen, Germany) providing photons of energies 15 and 6 MV. Proton beam treatment plans were
generated using passive double scattering technique (XiO, Nucletron) and therapy was delivered
with a cyclotron providing energies of 100 MeV – 230 MeV.
Concomitant chemotherapy with the cytostatic agent temozolomide was performed according to
Stupp et al. [1].
Image Acquisition
All imaging was performed on a 3T Philips Ingenuity TF PET/MRI scanner (Philips Healthcare,
Best, The Netherlands) with an 8-channel head-coil.
On each session, a 3D Turbo Field Echo T1-weighted (T1w) image was acquired with a 1 ×
1 × 1 mm3 resolution. A pseudo-continuous ASL sequence [21] with background suppression [22]
was used to acquire perfusion-weighted images as described in detail previously [15]: voxel size
2.75×2.75×6 mm3, 17 slices (0.6 mm gap), 2D echo-planar-imaging readout, TR/TE 3765/11 ms, 30
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averages, labeling time 1650 ms, post-labeling delay for the first and last slice 1525 and 2037 ms,
respectively. An M0 image was acquired with TR 5000 ms.
Preprocessing and perfusion quantification
All image processing was fully automatic and was done using SPM12 (Wellcome Trust Centre for
Neuroimaging, London, UK), and in-house routines written in Matlab (MathWorks, Natick, MA,
USA) based on ExploreASL, with specific modifications to accommodate brain deformations by the
tumor and surgery.
The T1w image was segmented using SPM12 [23] with enhanced tissue priors [24] providing a
relative content of GM, WM, and CSF in each voxel, see Supplementary Figure 1B. To avoid the
bias in segmentation caused by the presence of tumor and surrounding edema, both hemispheres
were segmented separately. The T1w image was rigid-body co-registered with the mean ASL control
image. Perfusion defined as regional cerebral blood flow (CBF) was quantified from the raw ASL data
using the single compartment model [25] and provided voxel-wise in mL/min/100 g, see perfusion
maps in Supplementary Figure 1D.
For the pre-therapeutic sessions, the CT image with the radiation dose map was co-registered
to the T1w image as shown in Supplementary Figure 1. For the post-therapeutic sessions, the
T1w images were non-linearly registered to the pre-therapeutic T1w images [26] to allow regional
comparison of dose and volumes across sessions.
Imaging data exclusion
ASL images were examined by two researchers (JP, HM) with 7 years of experience in ASL image
processing. Images with severe motion or acquisition artifacts were excluded from further analysis.
T1w images were examined by a radiologist (IP) with 12 years of experience. Images with severe
motion artifacts, which could lead to false decreases in GM volume [27], were excluded. Post-RCT
sessions with new morphological findings in WM compared to the pre-RCT baseline (e.g. edema,
leukoencephalopathy) were also excluded.
Post-RCT sessions with bilateral tumor progression, as assessed on contrast enhanced T1w images
and PET images, were excluded from both perfusion and volume analyses.
Statistical analysis
Between-session changes in brain volume and perfusion were evaluated in the healthy hemisphere
contralateral to the tumor. Volume of GM, WM, and total brain tissue (sum of GM and WM) in the
hemisphere contralateral to the tumor was calculated automatically from the segmented T1w images
by summing the voxel-wise tissue content across all voxels. Mean GM perfusion was calculated
as an average voxel-wise perfusion across the voxels with GM content exceeding 70%. Relative
volume and perfusion changes between sessions A and B were calculated as 100% ∗mean(valueB −
valueA)/mean(valueA) where valueA, valueB corresponded to the subject volume or perfusion on
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sessions A, B, respectively. A two-tailed paired t-test was used to assess the statistical significance of
the differences. Normality of the distribution was verified by a Shapiro-Wilk test prior to application
of the t-test. P < 0.05 was considered statistically significant in all analyses. Differences were
compared between the photon- and proton-therapy patient groups and also for the two subgroups
of the photon therapy – 3DCRT and IMRT.
To study radiation-dose dependence, dose regions were created for each participant by categoriz-
ing the voxels of the healthy hemisphere according to received dose into bins of 0–10, 10–60, 10–20,
20–30, 30–60 Gy. Both narrower bins and no division of regions with dose above 10 Gy were used
to be able to study high-dose regions in more detail and also to accommodate for the fact that the
amount of voxels in high-dose regions was small for the proton therapy. Statistical significance of
the differences from a zero change and a change compared to the region with dose below 10 Gy was
tested using simple and paired t-tests, respectively. For the perfusion analysis, dose-regions were
restricted to voxels with GM≥70% and regions smaller than 5 cm3 were excluded. For the volume
analysis, a threshold of 35 cm3 was used since this analysis was not restricted to GM voxels. Both
thresholds were approximately 5% of the total considered volume of around 150 cm3 (for perfusion)
and 700 cm3 (for volume).
Additionally, a multivariate linear regression was performed to investigate to what extent the
total tissue volume or perfusion was influenced by patient age, time from the baseline scan, and
mean dose received in the healthy hemisphere. The radiation modality was not included in the
multivariate analysis as it was strongly correlated with the mean dose (R=-0.80, P=1.2e-22).
RESULTS
Patient characteristics
After excluding images with artifacts, 41 photon- (22 3DCRT and 19 IMRT) and 16 proton-
therapy patients were included in the volume analysis, and 44 photon- (25 3DCRT and 19 IMRT) and
16 proton-therapy patients were included in the perfusion analysis, see Table 1. Details of exclusion
reasons are provided in Supplementary Tables 1 and 2. There was no difference between the proton-
and photon-therapy groups and subgroups in neither of age (P>0.25), ECOG score (P>0.11), BMI
(P>0.23), or chemotherapy duration (P>0.34) for neither of the volume and perfusion analysis.
CTV did not differ between proton and photon-therapy groups (P>0.73), but there was around 20%
difference between the two photon-therapy subgroups (P<0.022). Example of mean dose distribution
and dose histograms for the different RT modalities are shown in Supplementary Figure 3 and 4,
respectively. The average mean dose in the healthy hemisphere was 19.1 Gy for the CRT-, 26.2 Gy
for the IMRT-, 22.2 Gy for the photon-, and 4.2 Gy for the proton-therapy group and the difference
was significant between all groups.
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Tissue volume changes following RT treatment
For all photon-therapy patients on both follow-up sessions, both GM and WM volumes decreased
compared to the baseline (between -1.2 and -3.0%, P < 0.003, Table 2, Figure 1) whereas no
significant changes were observed for the proton-therapy patients (between 0.3 and -0.8%, P >
0.27, Table 2). The effect of RT modality on volume changes was significant (P=3 · 10−4). The
parenchymal volume seems to further decrease between the two post-therapeutic sessions (-0.8%,
P>0.027 for the photon-; and -0.8%, P>0.0025 for the proton-therapy group). The volume decreased
significantly for both the 3DCRT and IMRT subgroups with higher decrease in the IMRT group.
On the first post-therapy session, the volume decrease was significantly higher in both the 3DCRT
(P=0.045) and the IMRT (P=0.0049) groups than in the proton-therapy group, however, was not
different between the 3DCRT and IMRT groups (P=0.15).
Dose-dependent GM volume changes are provided in Table 3. The GM volume decreased signif-
icantly on the first post-therapeutic session compared to the pre-therapeutic session in all regions
for the photon-therapy patients (up to -3.1%, P = 10−5). In the regions with dose above 10 Gy, the
decrease was almost two times as high as in the region with dose below 10 Gy (-1.6%, P=0.026).
Significant decreases in GM volume on the second post-therapeutic session compared to the pre-
therapeutic session were also observed in all patients (between -1.6% and -3.6%, P < 0.018) except
in the region with dose below 10 Gy (-1.6%, P=0.12). Significant differences (P < 0.032) between
the volume decrease in high-dose (-3.2 – -4.1%) than in the low-dose (0.6 – -0.4%) regions were
observed in the proton-therapy as well despite the small size of the high-dose regions.
The results of the multivariate linear regression showed that the mean received dose in the
healthy hemisphere, time after treatment and age had a statistically significant effect on the volume
decrease of 0.9% / 10 Gy (P = 10−5), 0.25% / month (P=0.026), and 0.03% (P=0.021), respectively,
while the effect of sex (β=-0.59, P=0.13), BMI (β=0.07, P=0.14), chemotherapy duration (β=-0.02,
P=0.63), and CTV (β=0.00, P=0.74) was not statistically significant. Scatter plots of tissue-volume
decrease vs. mean dose, time, and age, respectively, are shown in Supplementary Figure 2.
Gray matter perfusion changes following RT treatment
The mean relative perfusion changes in the whole healthy hemisphere are shown in Table 4. Sta-
tistically significant decrease in perfusion was observed on both post-therapeutic sessions compared
to the pre-therapeutic session for the photon-therapy patients (relative change was -10.1%, P=0.002
on first; and -11.1%, P=0.008 on the second post-therapeutic session). The magnitude of the effect
was similar for the proton-therapy patients (-9.1%, P=0.12 on first; and -8.8%, P=0.17 on the second
post-therapeutic session). Although the perfusion decrease in proton-therapy patients did not reach
statistical significance there was no effect size difference between the photon- and proton-therapy
results (P=0.94). No significant change was observed between the two post-therapeutic sessions
7
(P>0.5). Although the perfusion decrease was higher for the IMRT than for the 3DCRT subgroup,
the difference was not significant on neither of the follow-up sessions (P>0.47).
The perfusion changes for different dose regions are shown in Table 5. For the photon-therapy
patients, significant perfusion decreases were observed for all doses above 10 Gy for the first post-
therapeutic session compared to the pre-therapeutic session. However, there were no significant
differences in perfusion decrease between regions below and above 10 Gy. In line with the ob-
served global perfusion decrease, perfusion decrease in proton-therapy patients was comparable in
magnitude, albeit not statistically significant.
The multivariate linear regression did not reveal significant effects of age (β=-0.24, P=0.15),
mean dose (β=0.10, P=0.64), time after therapy (β=-0.32, P=0.8), sex (β=-4.14, P=0.35), BMI
(β=-0.19, P=0.73), chemotherapy duration (β=0.50, P=0.30), or CTV (β=0, P=1.0) on whole-
hemisphere perfusion changes.
DISCUSSION
We compared the early-delayed effects of photon versus proton radiotherapy in the healthy brain
tissue of glioblastoma patients. Our three main findings are: (1) There was less brain-tissue volume
loss in patients who underwent proton-therapy compared to those who underwent photon-therapy;
(2) Loss of brain-tissue volume strongly correlated with the mean radiation dose received in the
healthy hemisphere; (3) Perfusion decreased in all patients, independent of therapy modality or
radiation dose. The effect size of the perfusion decrease following therapy was similar between the
two groups but reached statistical significance only for the photon-therapy patients. These findings
are in agreement with the hypothesis that proton therapy reduces the volume loss of healthy tissue
compared to photon therapy simply through limiting the radiation dose received in the contralateral
hemisphere.
The observation of brain-tissue loss in photon-therapy but not in proton-therapy patients, in
combination with the dose-dependency of the tissue loss suggests that brain volume changes are
caused mainly by the radiation effects. Normal aging is estimated to cause between 0.26% and 0.39%
per year decrease in GM volume, which is less than the values observed in the current study [28, 29].
A dose dependent GM-volume decrease was previously described by Karunamuni et al.[5]. Our
results are in agreement with their reported effect size (1 – 5% GM-volume decrease). However, the
results are not directly comparable as the probability distribution of volume changes and not the
mean volume changes were reported by Karunamuni et al.[5]. An approximately 5% GM-volume
decrease reported for the same tumor type and therapy by Prust et al.[4] in 8 patients is close to
our finding of 2 – 3% GM-volume decrease. The remaining difference could be caused by the fact
that Prust et al.[4] performed the T1w image segmentation in the whole brain at once without
excluding sessions with bilateral tumors and edemas in the contralateral hemisphere. The caveat is
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that the SPM12 segmentation employs a global model assuming homogeneous GM and WM intensity
distribution across the brain on the T1w images. Longitudinal intensity changes in WM around the
tumor (e.g. appearance of edema in follow-up measurement) will thus influence the segmentation
results also in the contralateral hemisphere and therefore can cause false classification of part of
GM tissue as WM, leading to false interpretation as a GM-volume decrease accompanied by a WM-
volume increase as noted by Chamberlain et al.[30]. False volume variations due to the mentioned
sources of error might explain why a WM-volume decrease has not been reported previously. We have
circumvented this issue by segmenting the healthy hemisphere separately and by also investigating
volume changes of GM and WM tissue combined.
In this study, approximately 10% perfusion decrease was present in both irradiation modalities
irrespective of the received radiation dose. The decrease was statistically significant for photon
therapy but not for proton therapy. Since the effect size and variability were similar for both
therapies the difference in statistical significance can be understood as a consequence of the smaller
sample size of the proton-therapy group.
Tumor perfusion measured in glioblastoma patients using MRI with or without contrast can
be used before or following RCT to detect residual or recurrent tumor, pseudo-progression or to
predict time to progression [31, 32, 33]. In such instances, tumor perfusion is often normalized
to perfusion in contralateral normal-appearing brain tissue. Therefore, our finding of perfusion
decreases in the normal-appearing brain tissue receiving relatively low radiation dose is a potential
confounder for the normalized perfusion and should be taken into consideration. While vascular
damage and neurocognitive deficits typically occur several years after RCT, we observed a perfusion
decrease three to six months after the therapy. In several recent studies, perfusion decrease has been
proposed as an early predictor of cognitive decline in neurodegenerative disease [34, 35] and similar
effects might be present following photon- or proton-based RCT. This, however, requires validation
by longer follow-up coupled with neurocognitive testing.
Previous studies that reported on perfusion changes following RCT were mostly conducted in
small populations and differed in received radiation dose, irradiation region definition, time after
RT, and imaging modality used. This may explain why previously reported results contradict one
another. Price et al.[14] observed a perfusion decrease only in the regions and above 32 Gy, Taki et
al.[13] reported 7% perfusion at 3 months after radiosurgery in a region that received less than 5 Gy,
and Hahn et al.[18] observed a CBF increase using [15O]H2O PET measurements. However, these
studies were conducted with 6 patients or less. Directly comparable to the current study in terms
of patient group characteristics, treatment type and statistical analysis is one investigation using
dynamic susceptibility contrast MRI [16] and our previous investigation using ASL [15]. Both show
similar results of around 10% GM CBF decrease in 10 and 24 patients, respectively. A small increase
in CBF with increased dose has been observed in all three of these studies without, however, reaching
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statistical significance. The changes in perfusion thus do not appear to be mainly caused by RT, but
seem related to either surgery, chemotherapy, or the disease itself. Especially the ongoing monthly
chemotherapy after the end of RT can cause further damage by the synergistic effect of chemo and
radiation therapy, as higher concentrations of chemotherapeutic agents in normal brain tissue is
achieved due to increased leakage through the bloodbrain barrier caused by RT [36]. The activity
of O6-Methylguanine-DNA methyltransferase (MGMT) has been related to both better therapeutic
response of glioblastoma and normal tissue protection to radiochemotherapy with O6-alkylating
agents such as temozolomide [37, 38]. While increase of MGMT activity could in theory play role in
the decrease of the perfusion and structural damage, we were not able to study this due to lack of
MGMT data in the normal tissue. We have observed higher, albeit mostly not significant, perfusion
and volume decreases in the IMRT group versus the 3DCRT group. For the volume changes, this
can be partly explained by the higher mean dose to the contralateral hemisphere in the IMRT group.
Only minimal correlation with mean dose, however, was found for the perfusion decrease. The reason
for the differences in the perfusion changes can thus be either a larger relative volume irradiated to
high radiation doses of ¿ 30 Gy or by another, unknown effect. There was a significant difference
in the CTV between the 3DCRT and the IMRT groups. It thus remains difficult to assess to what
extent the difference in radiation dose was caused by the varying CTV or the radiation treatment
technique. Although the CTV difference was not large, further studies are needed to provide an
unbiased comparison of the effects of 3DCRT and IMRT on the healthy hemisphere.
Our findings indicate that early-delayed brain-tissue volume changes are strongly dependent
on the radiation dose applied to the healthy brain, suggesting that a reduced dose to brain-tissue
may reduce regional loss of brain volume. Indeed, proton-therapy patients were shown to have
significantly lower loss of brain tissue than the photon-therapy patients. On the other hand, perfusion
decreased irrespective of the beam modality. Both longer follow-up in a larger cohort, as well as
neurocognitive testing may allow to further explore the underlying pathological pathways of primary
and secondary damage and its effect on cognitive function and to investigate if these benefits of
proton therapy prevail over longer time.
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Table 1: Patients’ demographics.
Volume analysis Perfusion analysis
Photon Proton Photon Proton
Patients [n] 41 16 44 16
Male/female [n] 24/17 10/6 24/20 11/5
Mean age [years] 55.9±13.9 51.3±16.3 55.4±13.3 51.5±16.2
Age range [years] 25.3–81.8 23.2–72.4 25.3–75.3 23.2–72.4
ECOG Score 0.5±0.6 0.4±0.5 0.6±0.6 0.5±0.6
BMI [kg/m2] 26.2±4.8 24.9±3.9 26.3±4.6 25.9±3.8
Tumor hemisphere [L/R] 19/22 10/6 21/23 11/5
Tumor location
Frontal 21 5 22 7
Temporal 9 7 6 6
Parietal 3 2 5 1
Occipital 2 0 3 0
Frontotemporal 0 1 0 1
Temporooccipital 3 1 4 1
Parietooccipital 1 0 1 0
Thalamus 2 0 2 0
Cerebellum 0 0 1 0
Biopsy only 2 0 2 0
CTV [mm3] 224.8±224.8 217.4±217.4 226.8±226.8 229.4±229.4
Mean dose [Gy] 22.6±6.6 4.0±4.4 22.4±7.1 4.9±4.4
Simultaneous TMZ [days] 40.2±4.8 38.4±7.5 40.5±4.6 39.8±5.6
Dexamethasone [n (%)] 4 (10%) 1 (6%) 5 (11%) 1 (6%)
Patients’ demographics of the groups of photon and proton-therapy patients used for the volume and perfusion
analysis. Additionally, the clinical target volume, the mean radiation dose in the healthy hemisphere, the number
of days during which 75 mg/m2/day of Temozolomide was administered simultaneously to the RT treatment, and
the number of patients receiving Dexamethasone in time between the baseline and second follow-up measurement
are given. The difference between the two photon-therapy groups and between the proton-therapy group was not
significant (P>0.05) for neither of the parameters (Age, ECOG, BMI and TMZ) for neither of the analysis (volume,
perfusion). CTV was different between the two photon-therapy subgroups (P<0.022) but not between proton and
photon-therapy groups (P>0.73). Mean dose was different both between the two photon-therapy subgroups (P<0.002)
and between the proton- and photon-therapy groups (P< 10−8).
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Table 2: Global brain volume changes in the healthy hemisphere.
RT Session num. interval ∆GM ∆WM ∆Tissue
modal. A B of pat. [months] [%] P [%] P [%] P
Photon
Pre Post-1 40 4.7±0.4 -2.2±3.0 6 · 10−5 -1.2±1.9 0.0004 -1.7±1.7 10−7
Pre Post-2 24 7.9±0.5 -2.2±3.2 0.003 -3.0±2.6 10−5 -2.5±2.0 2 · 10−6
Proton
Pre Post-1 15 4.7±0.4 0.3±2.3 0.64 -0.4±3.0 0.58 -0.0±1.9 0.98
Pre Post-2 12 8.0±0.7 -0.8±2.8 0.36 -1.0±3.0 0.27 -0.9±2.1 0.2
3DCRT
Pre Post-1 21 4.7±0.4 -1.4±2.8 0.035 -1.4±1.9 0.003 -1.4±1.6 0.001
Pre Post-2 13 7.9±0.5 -1.1±3.4 0.29 -2.7±3.2 0.01 -1.8±2.1 0.012
IMRT
Pre Post-1 19 4.7±0.4 -3.0±3.0 0.0005 -0.9±2.0 0.058 -2.1±1.7 4 · 10−5
Pre Post-2 11 7.9±0.5 -3.6±2.3 0.0005 -3.5±1.8 5 · 10−5 -3.5±1.3 4 · 10−6
Tissue volume changes for the first (Post-1) and second (Post-2) post-radiotherapy sessions are shown compared
to the pre-therapy baseline (Pre). Significant mean relative volume decreases in GM, WM, and brain tissue were
observed in the photon-therapy patients. Volume changes in the proton-therapy patients were not significant and the
magnitudes of the changes were also much smaller than in the photon-therapy patients. Results are shown also for
the two subgroups of the photon-therapy patients. Volume decreased in both subgroups on both sessions and the
effect was stronger in the IMRT than in the 3DCRT patients.
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Table 3: Dose-dependent brain volume changes in the healthy hemisphere.
Photon Dose [Gy] 0–10 10–60 10–20 20–30 30–60
Pre ∆GM [%] -1.6 -2.4 -1.8 -2.9 -3.1
/ Region size [%/n] 23% / 32 77% / 40 27% / 39 21% / 34 29% / 37
Post-1 P-value [0] 0.026? 10−5?? 0.0004?? 3 · 10−6?? 10−5??
P-value [LD] – 0.027? 0.032? 0.067 0.014?
Pre ∆GM [%] -1.6 -2.5 -1.8 -2.5 -3.6
/ Region size [%/n] 21% / 17 79% / 24 29% / 23 20% / 20 29% / 22
Post-2 P-value [0] 0.12 0.0008?? 0.018? 0.004? 6 · 10−5??
P-value [LD] – 0.31 0.78 0.45 0.13
Proton Dose [Gy] 0–10 10–60 10–20 20–30 30–60
Pre ∆GM [%] 0.6 -3.2 – – –
/ Region size [%/n] 91% / 15 9% / 6 2% / 0 2% / 0 5% / 6
Post-1 P-value [0] 0.3 0.14 – – –
P-value [LD] – 0.0063? – – –
Pre ∆GM [%] -0.4 -4.1 – – –
/ Region size [%/n] 90% / 12 10% / 7 2% / 0 2% / 0 6% / 7
Post-2 P-value [0] 0.57 0.082 – – –
P-value [LD] – 0.032? – – –
The mean relative GM volume changes are shown for several dose regions. Note that the effect size and P -values are
not given for regions (mainly proton therapy) with relative size under 7% as they were considered too much affected by
noise. For each session, the mean dose-region volume as a percentage of the whole-hemisphere volume, and the number
of regions that exceeded the 35 cm3 threshold are given. The P -values of the t-tests for probability of no absolute
change [0] and no change relative to the low dose (below 10 Gy) region [LD] are shown. Statistically significant values
are labeled by ? for P < 0.05 and by ?? for P < 0.001. For the photon-therapy patients, a significant decrease of GM
volume was observed for all doses except for the region with dose below 10 Gy on the second post-therapeutic session.
On the first post-therapeutic session, significantly higher GM volume decrease was observed in the regions above 10
Gy than in the region below 10 Gy. None of the proton-therapy results were significant.
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Table 4: Global perfusion changes in the healthy hemisphere.
RT Session number of interval CBFA CBFB ∆CBF P -value
modal. A B patients [months] mean±std [mL/min/100 g] mean±std [%]
Photon
Pre Post-1 41 4.7±0.4 53.4±9.7 48.0±9.6 -10.1±19.9 0.002
Pre Post-2 26 7.8±0.5 53.4±10.7 47.5±8.9 -11.1±19.5 0.008
Proton
Pre Post-1 15 4.8±0.5 50.3±8.4 45.8±8.6 -9.1±21.6 0.12
Pre Post-2 11 8.0±0.6 52.7±8.2 48.0±11.1 -8.8±19.7 0.17
3DCRT
Pre Post-1 24 4.9±0.3 53.0±8.8 48.8±9.4 -7.9±19.4 0.061
Pre Post-2 13 7.9±0.6 51.8±8.8 47.5±10.0 -8.2±14.7 0.07
IMRT
Pre Post-1 17 4.6±0.5 53.9±11.2 46.8±10.1 -13.1±20.9 0.01
Pre Post-2 13 7.7±0.4 55.0±12.4 47.4±8.0 -13.7±24.0 0.055
Perfusion changes are shown for photon- (top) and proton-therapy patients (bottom). On each line, the absolute
CBF, number of available patients, time between the sessions, the mean relative CBF difference between sessions,
and the P -value of the paired t-test between the pre-therapeutic (Pre-) and one of the two post-therapeutic sessions
(Post-1 and Post-2) are shown. The magnitudes of changes were similar for all sessions and RT modalities, however,
the changes were significant only for the photon-therapy patients. Results are shown also for the two subgroups of
the photon-therapy patients. While magnitude of changes is again similar, significant decrease is observed only on the
first post-therapeutic session of the IMRT patients where the magnitude of decrease is higher than for the 3DCRT
patient group.
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Table 5: Dose-dependent perfusion changes in the healthy hemisphere.
Photon Dose [Gy] 0–10 10–60 10–20 20–30 30–60
Pre ∆CBF [%] -7.3 -8.3 -8.9 -8.5 -8.7
/ Region size [%/n] 26% / 36 74% / 41 28% / 40 19% / 36 26% / 41
Post-1 P-value [0] 0.057 0.009? 0.006? 0.017? 0.007?
P-value [LD] – 0.39 0.21 0.3 0.4
Pre ∆CBF [%] -7.3 -8.8 -10.3 -8.0 -8.0
/ Region size [%/n] 27% / 21 73% / 26 29% / 26 20% / 21 24% / 25
Post-2 P-value [0] 0.15 0.029? 0.007? 0.09 0.061
P-value [LD] – 0.51 0.27 0.18 0.51
Proton Dose [Gy] 0–10 10–60 10–20 20–30 30–60
Pre ∆CBF [%] -7.0 -9.5 – – –
/ Region size [%/n] 90% / 15 10% / 8 2% / 1 2% / 3 7% / 8
Post-1 P-value [0] 0.23 0.25 – – –
P-value [LD] – 0.75 – – –
Pre ∆CBF [%] -8.3 -7.4 – – –
/ Region size [%/n] 91% / 11 9% / 7 2% / 2 1% / 3 6% / 7
Post-2 P-value [0] 0.19 0.36 – – –
P-value [LD] – 0.43 – – –
The mean relative perfusion changes are shown for different dose regions for photon- and proton-therapy patients.
Note that effect size and P -values are not given for the finer division of the regions above 10 Gy for the proton-
therapy patients as the region size was too small to give meaningful results. The mean volume of the dose region as a
percentage of the whole hemisphere, and the number of patients for which the region volume exceeded the threshold
of 5 cm3 are shown as Region size. The P -values of the t-test indicate probability of no absolute change [0 ] and no
change relative to the low-dose (below 10 Gy) region [LD ]. Significant values are labeled by ? for P < 0.05, and by
?? for P < 0.001. Significant perfusion decreases were observed in all dose regions above 10 Gy in photon-therapy
patients on the first post-therapeutic session. However, the results for regions above 10 Gy were not significantly
different from the change in the region below 10 Gy. Effect size was similar in the proton-therapy patients, though
the differences were not statistically significant.
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FIGURE LEGENDS
Figure 1: Progressive brain atrophy. T1w images of an IMRT photon-therapy patient are shown for pre- (A)
and post-therapeutic (B,C) sessions. Brain atrophy manifests as ventrical and outer CSF space enlargement (see, for
example, anterior portion of cella media). Tissue volume decrease on the first post-therapeutic session (B) compared
to the pre-therapeutic baseline (A) was 1.8%. Progression of the atrophy is observed on the second post-therapeutic
session (C): 4.2% decrease compared to the pre-therapeutic baseline (A).
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SUPPLEMENTARY MATERIALS
Figure 1: Images from representative patients are shown for 3DCRT photon (A-D) and proton (E-H) therapy.
T1-weighted (T1w) images (A,E) were segmented to GM, WM and CSF in each voxel. The T1w are shown overlaid
with the voxel-wise map of GM segmentation (B,F), the calculated radiation-dose (C,G), and the perfusion image
(D,H). Note the difference in dose distribution between both radiotherapy (RT) modalities and sparing of healthy
tissue distal of the target volume achieved with proton therapy.
Photon Proton
Reason 3DCRT IMRT
WM changes [n] 1 5 4
Missing or motion [n] 4 1 2
Bilateral tumor [n] 0 1 3
Table 1: Exclusion from the volume analysis. Sessions with T1w images with visible changes in WM contrast
in the healthy hemisphere compared to the pre-RCT session (edema, leukoencephalopathy, demyelinization), severe
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Figure 2: Univariate regression of global volume changes. The scatter plots show the dependence of tissue-
volume changes on A) mean dose received in the hemisphere contralateral to the tumor, B) patient age, C) time after
the baseline pre-therapeutic scan (blue: photon-therapy, red: proton-therapy) . The Pearson’s correlation coefficient
(r) and the parameters and p-value of linear regression with y = a + b × x are given in each plot. While statistical




Motion [n] 0 2 1
Labeling [n] 0 1 0
Bilateral tumor [n] 0 1 2
Missing ASL [n] 1 0 4
ATT artifacts [n] 3 3 3
Table 2: Exclusion from the perfusion analysis. ASL images with severe motion artifacts, failure of blood
labeling, bilateral tumor presence, or sessions where ASL was not acquired for technical reasons were excluded from
the perfusion analysis.
Figure 3: Mean dose in the healthy hemisphere for the two photon-therapy subgroups A) 3D conformal radiotherapy
(3DCRT), B) intensity-modulated radiotherapy (IMRT), C) all photon- and D) all proton-therapy patients. Mean
dose over the healthy hemisphere was calculated for each group and combined result is shown for patient with tumor
in the left and in the right hemisphere which explains the discontinuity at the midline.
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Figure 4: Dose distribution in the healthy hemisphere for the photon- and proton-therapy patients and the two
photon-therapy subgroups. Mean relative volume for each isodose region is shown as a fraction of the whole-hemisphere
volume. Note that both bins of 0-10 and 10-60 Gy, and bins of 0-10, 10-20, 20-30 and 30-60 Gy add up to 100%.
The proton-therapy clearly spares the healthy hemisphere more than all photon-therapies with only minimal volume
receiving dose above 10 Gy. IMRT has slightly higher relative volume above 20 Gy than the 3DCRT planning which
is both due to the inherent properties of the planning and slightly larger CTV in the IMRT group than in the 3DCRT
group.
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